Does Anthem (Elevance Health) Cover Lisinopril?

What Anthem's Standard Formulary Says About Lisinopril

Lisinopril sits on Tier 1 of Anthem's commercial formulary in the vast majority of plan designs, meaning members pay the lowest available copay, typically $0 to $10 per 30-day fill. The drug lost patent protection decades ago, and generic manufacturers now supply it at commodity prices. Anthem's publicly available Evidence of Coverage documents confirm that generic ACE inhibitors are preferred agents for cardiovascular indications.

The FDA approved lisinopril for hypertension in 1987, for heart failure in 1992, and for acute myocardial infarction (MI) in 1993 [1]. Diabetic nephropathy was added later based on landmark renal-protection data. Because lisinopril has FDA approval for these high-prevalence conditions, formulary placement as a preferred generic is standard practice across major commercial insurers, not just Anthem [2].

Dose ranges covered under a standard fill are 2.5 mg to 40 mg tablets once daily, consistent with the prescribing label [1]. Split-tablet prescribing (for example, 20 mg tablets split to achieve a 10 mg dose) is common and pharmacy-dispensed without issue on most Anthem plans, reducing cost further.

Anthem's pharmacy benefit is administered in-house or through a PBM partner depending on employer contract. The plan's Drug List (formulary) is updated quarterly, so tier placement should be verified at anthem.com or by calling the member services number on the back of your insurance card before filling [3].

Prior Authorization Requirements for Lisinopril on Anthem

For standard indications, hypertension, systolic heart failure, and chronic kidney disease (CKD), Anthem does not require prior authorization (PA) for lisinopril in most commercial plan designs. The drug's generic status, low cost, and guideline-preferred position make PA an unnecessary administrative layer from a payer perspective.

The 2023 ACC/AHA Hypertension Guideline lists ACE inhibitors as first-line agents for patients with hypertension plus CKD, heart failure with reduced ejection fraction (HFrEF), or diabetes [4]. Anthem's medical policy generally mirrors major society guidelines for formulary management, which supports the no-PA default.

PA may be triggered in two narrower scenarios. First, if a member's employer-sponsored self-funded plan uses a custom formulary with stricter utilization management, PA could apply. Second, prescriptions written for off-label uses, such as migraine prophylaxis or polycystic kidney disease, may require PA with clinical documentation [5]. Always check the specific plan's Summary of Benefits and Coverage (SBC) before assuming no PA is needed.

When PA is required, Anthem's standard criteria typically ask for: a confirmed diagnosis (ICD-10 code), documented blood pressure readings or lab values (eGFR for CKD), prescriber attestation that the patient is not pregnant (lisinopril is contraindicated in pregnancy per the FDA black-box warning), and absence of prior ACE inhibitor-related angioedema [1]. Turnaround for a standard PA request is 72 hours; urgent requests must be processed within 24 hours under CMS rules [6].

Does Anthem Require Step Therapy Before Lisinopril?

Step therapy is uncommon for lisinopril specifically because it is already the generic, lower-cost agent at the bottom of the ACE inhibitor ladder. Step therapy typically requires a trial of a cheaper drug before a more expensive one, and lisinopril is frequently the cheaper drug payers want members on [7].

A subset of employer-sponsored plans with custom formularies may require a 30-day trial of another generic ACE inhibitor (for example, enalapril or ramipril) before authorizing lisinopril fills at the preferred tier. This is rare and driven by specific pharmacy benefit contract terms negotiated between the employer and the PBM, not Anthem's default policy.

ALLHAT (the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, N=33,357) found that lisinopril, amlodipine, and chlorthalidone produced similar rates of fatal coronary heart disease and nonfatal MI over a mean 4.9-year follow-up [8]. The trial did find higher stroke rates in the lisinopril arm (6.3% vs. 5.6% for chlorthalidone, P<0.001), which informs some payer policies preferring thiazides as first-step agents for uncomplicated hypertension [8]. If your plan requires thiazide step therapy before an ACE inhibitor, your prescriber can document a contraindication or intolerance to thiazides to bypass the step [9].

The 2022 KDIGO CKD Guideline recommends ACE inhibitors as first-line agents (not step-therapy fallbacks) for patients with CKD and albuminuria exceeding 30 mg per gram creatinine, which gives prescribers strong grounds to skip thiazide step therapy in that population [10].

How to Check Your Specific Anthem Plan's Lisinopril Coverage

Coverage details vary by plan. Here is a four-step process to confirm before the pharmacy runs your claim.

Step 1. Log in to anthem.com, manage to "Find a Drug," and enter "lisinopril" with your dose. The tool displays tier, copay, and any coverage restrictions in real time.

Step 2. Download the current-year Summary of Benefits and Coverage (SBC) from your employer benefits portal. The SBC includes the formulary tier for generics and the applicable cost-sharing structure [11].

Step 3. Call member services at the number printed on the back of your Anthem card. Ask specifically: "Is lisinopril [dose] covered on my formulary, and is prior authorization or step therapy required?" Document the date, representative name, and reference number.

Step 4. Ask your pharmacist to run a test claim before you arrive to pick up the prescription. Most pharmacy dispensing software returns real-time adjudication data, including whether PA is needed.

What Lisinopril Actually Costs With and Without Anthem Coverage

Lisinopril's manufacturer list price is roughly $50 per month for brand-name Zestril, but virtually no patient fills brand-name lisinopril in 2025. The generic costs about $8 per month at GoodRx-participating pharmacies with a discount card, and about $4 per month at Walmart's $4 generic program for a 30-day supply of 10 mg or 20 mg tablets [12].

With a Tier 1 Anthem benefit, members typically pay $0 to $10 per 30-day fill and $0 to $25 per 90-day fill through Anthem's mail-order pharmacy, IngenioRx. The math strongly favors in-network fills for members with active coverage.

For members in the deductible phase of a high-deductible health plan (HDHP), the generic cash price ($8 to $12) is often lower than the insurance-negotiated rate posted to the deductible. Asking the pharmacist to run it as cash rather than insurance during the deductible phase can save money [12].

Manufacturer savings cards do not apply to lisinopril because no brand-name manufacturer is actively marketing a co-pay assistance program for a decades-old generic. Patients who need cost help should use GoodRx, RxSaver, or the pharmacy's own generic pricing program instead.

The FDA's Orange Book lists more than 30 approved generic manufacturers of lisinopril, ensuring supply competition that keeps prices low [13]. Shortages are rare; the drug has maintained consistent availability since generic entry.

What to Do If Anthem Denies Lisinopril Coverage

Denials for lisinopril are uncommon given its generic status and broad indication coverage, but they do occur, most often for off-label uses or when a custom formulary excludes it. If your claim is denied, Anthem is required by federal law to provide a written denial notice explaining the reason and the appeal process [14].

Internal Appeal. File within 180 days of the denial (or the shorter timeline stated in your plan documents). Submit the following: the denial notice, a letter of medical necessity from your prescriber, relevant lab results (blood pressure readings, eGFR values), and supporting guideline citations. The ACC/AHA 2023 Hypertension Guideline and the 2022 KDIGO CKD Guideline are both strong references to include [4][10]. Anthem must decide urgent appeals within 72 hours and standard appeals within 30 days [14].

External Review (State IRO). If Anthem upholds the denial, you may request external review by an Independent Review Organization (IRO) certified in your state. All states plus Washington D.C. Have IRO programs. Federal employees on FEHB plans use the OPM-designated external reviewer instead [15]. IRO decisions are binding on the insurer.

State Insurance Commissioner Complaint. Filing a complaint with your state's Department of Insurance is a parallel option that is separate from the formal appeal. It creates a regulatory record and sometimes prompts faster reconsideration, particularly for clearly guideline-supported drugs.

The AHA's 2021 Scientific Statement on Social Determinants of Health notes that medication non-adherence due to cost is associated with a 10% to 25% increase in cardiovascular event risk, which is a point worth making in any appeal letter arguing medical necessity [16].

Lisinopril's Clinical Evidence Base That Supports Coverage

Payers use clinical evidence to set coverage policy. Understanding the trial record helps prescribers write stronger PA letters and appeal documents.

ALLHAT (N=33,357) remains the largest hypertension outcomes trial ever conducted in the United States. Published in JAMA in 2002, it found lisinopril reduced diastolic blood pressure by a mean 8.8 mmHg over 4.9 years in Black and non-Black participants combined [8]. The trial's finding of similar fatal CHD and nonfatal MI rates across treatment arms established lisinopril as an acceptable first-line agent, not a step-therapy fallback.

The GISEN Group's REIN trial (N=352) showed that ramipril (a related ACE inhibitor) reduced the rate of GFR decline in patients with non-diabetic CKD and proteinuria exceeding 3 g per day, supporting ACE inhibitor use across the CKD spectrum [17]. Anthem's own medical policy for CKD management cites ACE inhibitor evidence from trials in this class [3].

SOLVD-Treatment (N=2,569) demonstrated that enalapril reduced all-cause mortality by 16% (P<0.001) in patients with HFrEF (EF <35%) over 41.4 months, supporting class-level coverage of ACE inhibitors for heart failure [18]. Lisinopril carries the same indication, and this trial is routinely cited in formulary justifications.

The FDA's 2020 Drug Safety Communication reinforced the black-box warning against ACE inhibitor use in pregnancy, noting fetal renal dysgenesis and death risks [19]. PA criteria that require pregnancy status documentation are grounded in this safety concern, not designed as a coverage barrier.

JNC 8 (published in JAMA 2014, N=guideline synthesis) recommended ACE inhibitors or ARBs as preferred first-line agents in patients with CKD, regardless of race, at a blood pressure target of <140/90 mmHg [20]. That recommendation directly supports formulary coverage without step therapy for CKD patients.

Lisinopril and Anthem Medicaid or Medicare Plans

Anthem administers Medicaid managed care in multiple states under names such as Anthem HealthKeepers Plus, Amerigroup, and Simply Healthcare. In these plans, lisinopril is covered as a preferred generic with $0 or very low cost-sharing for eligible members, consistent with state Medicaid formulary requirements [21].

On Anthem's Medicare Advantage (MA) plans and Part D standalone PDPs, lisinopril appears on Tier 1 of the formulary. CMS requires Part D sponsors to cover all or substantially all drugs in the ACE inhibitor class, and lisinopril is one of the most commonly included agents [22]. Members in the initial coverage phase pay their plan's generic copay; those in the catastrophic coverage phase may pay as little as $0 per fill starting in 2025 under the Inflation Reduction Act changes to Part D [23].

Medicare Part D plans administered by Anthem use the IngenioRx PBM platform. The formulary is filed annually with CMS and cannot be changed mid-year except in narrow circumstances [22]. Members can compare Part D formularies at medicare.gov/plan-compare.

Dual-eligible members (Medicare and Medicaid) typically have $0 cost-sharing for all Part D generics under the Low Income Subsidy (LIS) program [23]. Lisinopril's Tier 1 status makes it fully covered at no cost for this population.

Special Populations: Pregnancy, Pediatrics, and Renal Dosing

Lisinopril is absolutely contraindicated in pregnancy. The FDA black-box warning states that ACE inhibitors can cause fetal renal tubular dysplasia, skull hypoplasia, and death when used in the second and third trimesters [1][19]. Anthem's PA criteria for reproductive-age women may include a pregnancy attestation for this reason. No coverage appeal can override a contraindication grounded in patient safety.

In pediatric patients aged 6 to 16 with hypertension and eGFR above 30 mL/min/1.73m2, lisinopril is FDA-approved at 0.07 mg/kg once daily (up to 5 mg) [1]. Anthem's pediatric formulary covers this indication. Patients under 6 or with eGFR below 30 mL/min/1.73m2 are excluded from the labeled pediatric population [1].

Renal dose adjustment is required. The FDA label recommends starting doses of 2.5 mg for patients with eGFR below 30 mL/min/1.73m2 and contraindication in patients on dialysis [1]. Prescriptions written for doses inconsistent with renal function may trigger a pharmacist DUR (Drug Utilization Review) alert; this is a safety check, not a coverage denial.

Lisinopril Drug Interactions That May Affect Coverage Documentation

Anthem's PA criteria occasionally ask about concomitant medications, particularly when dual RAAS blockade is being prescribed. The FDA issued a Safety Communication in 2012 warning against combined use of ACE inhibitors and ARBs (for example, lisinopril plus losartan) due to increased risk of hypotension, hyperkalemia, and renal impairment without added cardiovascular benefit [24]. If a PA is requested for lisinopril in a patient already on an ARB, Anthem may require documentation of the clinical rationale.

Combined use of lisinopril with sacubitril/valsartan (Entresto) is also contraindicated for 36 hours before and after Entresto administration due to angioedema risk [25]. Anthem's utilization management may flag concurrent prescriptions. This is again a safety consideration built into PA criteria.

Potassium-sparing diuretics (spironolactone, amiloride) and potassium supplements used alongside lisinopril can cause clinically significant hyperkalemia, a finding supported by a 2015 JAMA Internal Medicine analysis showing a 1.5-fold increase in hyperkalemia hospitalizations with combined use [26]. Prescribers should document potassium monitoring plans in PA submissions involving these combinations.